These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 29869806)
1. Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation. Bruneel A; Cholet S; Drouin-Garraud V; Jacquemont ML; Cano A; Mégarbané A; Ruel C; Cheillan D; Dupré T; Vuillaumier-Barrot S; Seta N; Fenaille F Electrophoresis; 2018 Dec; 39(24):3123-3132. PubMed ID: 29869806 [TBL] [Abstract][Full Text] [Related]
2. Clinical glycomics for the diagnosis of congenital disorders of glycosylation. Abu Bakar N; Lefeber DJ; van Scherpenzeel M J Inherit Metab Dis; 2018 May; 41(3):499-513. PubMed ID: 29497882 [TBL] [Abstract][Full Text] [Related]
3. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG). Casetta B; Malvagia S; Funghini S; Martinelli D; Dionisi-Vici C; Barone R; Fiumara A; Donati MA; Guerrini R; la Marca G Clin Chem Lab Med; 2020 Aug; 59(1):165-171. PubMed ID: 32776892 [TBL] [Abstract][Full Text] [Related]
4. MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis. Yen-Nicolaÿ S; Boursier C; Rio M; Lefeber DJ; Pilon A; Seta N; Bruneel A Proteomics Clin Appl; 2015 Aug; 9(7-8):787-93. PubMed ID: 25641685 [TBL] [Abstract][Full Text] [Related]
5. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients. Vals MA; Ashikov A; Ilves P; Loorits D; Zeng Q; Barone R; Huijben K; Sykut-Cegielska J; Diogo L; Elias AF; Greenwood RS; Grunewald S; van Hasselt PM; van de Kamp JM; Mancini G; Okninska A; Pajusalu S; Rudd PM; Rustad CF; Salvarinova R; de Vries BBA; Wolf NI; ; Ng BG; Freeze HH; Lefeber DJ; Õunap K J Inherit Metab Dis; 2019 May; 42(3):553-564. PubMed ID: 30746764 [TBL] [Abstract][Full Text] [Related]
6. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Xia B; Zhang W; Li X; Jiang R; Harper T; Liu R; Cummings RD; He M Anal Biochem; 2013 Nov; 442(2):178-85. PubMed ID: 23928051 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic and genotypic spectrum of congenital disorders of glycosylation type I and type II. Al Teneiji A; Bruun TU; Sidky S; Cordeiro D; Cohn RD; Mendoza-Londono R; Moharir M; Raiman J; Siriwardena K; Kyriakopoulou L; Mercimek-Mahmutoglu S Mol Genet Metab; 2017 Mar; 120(3):235-242. PubMed ID: 28122681 [TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation. Wada Y Glycoconj J; 2016 Jun; 33(3):297-307. PubMed ID: 26873821 [TBL] [Abstract][Full Text] [Related]
9. High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation. van Scherpenzeel M; Steenbergen G; Morava E; Wevers RA; Lefeber DJ Transl Res; 2015 Dec; 166(6):639-649.e1. PubMed ID: 26307094 [TBL] [Abstract][Full Text] [Related]
10. Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue! Raynor A; Vincent-Delorme C; Alaix AS; Cholet S; Dupré T; Vuillaumier-Barrot S; Fenaille F; Besmond C; Bruneel A Clin Chim Acta; 2021 Aug; 519():285-290. PubMed ID: 34022244 [TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein C-III O-glycoform profiling of 500 serum samples by matrix-assisted laser desorption/ionization mass spectrometry for diagnosis of congenital disorders of glycosylation. Wada Y; Okamoto N J Mass Spectrom; 2021 Apr; 56(4):e4597. PubMed ID: 32677746 [TBL] [Abstract][Full Text] [Related]
12. Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1. Abu Bakar N; Ashikov A; Brum JM; Smeets R; Kersten M; Huijben K; Keng WT; Speck-Martins CE; de Carvalho DR; de Rizzo IMPO; de Mello WD; Heiner-Fokkema R; Gorman K; Grunewald S; Michelakakis H; Moraitou M; Martinelli D; van Scherpenzeel M; Janssen M; de Boer L; van den Heuvel LP; Thiel C; Lefeber DJ J Inherit Metab Dis; 2022 Jul; 45(4):769-781. PubMed ID: 35279850 [TBL] [Abstract][Full Text] [Related]
13. Relative quantification of plasma N-glycans in type II congenital disorder of glycosylation patients by mass spectrometry. Barbosa EA; Fontes NDC; Santos SCL; Lefeber DJ; Bloch C; Brum JM; Brand GD Clin Chim Acta; 2019 May; 492():102-113. PubMed ID: 30776362 [TBL] [Abstract][Full Text] [Related]
14. Increased Clinical Sensitivity and Specificity of Plasma Protein Chen J; Li X; Edmondson A; Meyers GD; Izumi K; Ackermann AM; Morava E; Ficicioglu C; Bennett MJ; He M Clin Chem; 2019 May; 65(5):653-663. PubMed ID: 30770376 [TBL] [Abstract][Full Text] [Related]
15. MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG. Palmigiano A; Bua RO; Barone R; Rymen D; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Garozzo D; Jaeken J; Sturiale L J Mass Spectrom; 2017 Jun; 52(6):372-377. PubMed ID: 28444691 [TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry in the characterization of human genetic N-glycosylation defects. Barone R; Sturiale L; Garozzo D Mass Spectrom Rev; 2009; 28(3):517-42. PubMed ID: 18844296 [TBL] [Abstract][Full Text] [Related]